Company Overview: Oxford Biomedica PLC (LSE: OXB): is a United Kingdom-based cell and gene therapy research, development, and bio-processing company, listed on the FTSE All-Share index. The company offers services to third parties and conducts internal research and development for its own purposes. Within its in-house quality check (QC) labs, Oxford Biomedica performs a variety of analytical assays. The Platform segment is engaged in bio-processing and processes development activities conducted on behalf of third parties, particularly as part of the partner program for LentiVector and AAV (adeno-associated virus) CDMOs (contract development and manufacturing organizations) business. This Report covers the Price Action, Technical Indicators Analysis along with the Support Levels, Resistance Levels, and Recommendations on this stock.

OXB’s Fundamental Commentary:

The Company anticipates FY23 revenue to reach approximately £90 million, with an Operating EBITDA loss expected to improve by around £10 million in H2 FY23 compared to H1 FY23. Looking ahead to FY24, the company projects top-line revenue to range between £126 million and £134 million. Additionally, OXB foresees a three-year revenue compound annual growth rate (CAGR) of more than 35% for the period spanning 2023 to 2026. In terms of profitability, OXB aims to achieve Operating EBITDA margins exceeding 20% by the end of 2026. Overall, the Company remains confident in accelerating its financial performance, driven by a growing order book and operational advancements.

OXB’s Technical Observation:

OXB’s prices have recently undergone a correction, but the management's presentation of new guidelines and growth outlook for the upcoming months has elicited a positive reaction from the market. Consequently, the stock price has broken above the rising trendline with momentum. There is anticipation of a reversal in the Current Market Price (CMP) of GBX 217.48, supported by a strong volume buildup. The leading indicator RSI (14-period) is at 64.29, suggesting a bullish trend in the price. Moreover, the CMP is trading above both the trending indicators, the 21-period SMA and the 50-period SMA, indicating their potential role as support levels in the near term. The important support levels for the stock are situated at GBX 191.50 and GBX 182.00, while key resistance is positioned at GBX 240.00 and GBX 258.00 levels.

OXB’s Daily Chart

As per the above-mentioned price action and technical indicators analysis, a ‘Speculative Buy’ rating has been given on Oxford Biomedica PLC (LSE: OXB) at the Current Price of GBX 217.48, as of 9:20 AM (GMT+1), April 24, 2024. Oxford Biomedica PLC (LSE: OXB) was last covered in a report dated 15^th February 2023'. Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario.

Markets are trading in a highly volatile zone currently due to certain Macro & Micro-economic data and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Note 1: Related Risks: This report may be looked at from a high-risk perspective and recommendations are provided for a short duration. Recommendations provided in this report are solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rate risks, currency risks, social and political instability risks etc.

Note 2: How to Read the Charts?

The Green colour line reflects the 21-period moving average while the red line indicates the 50- period moving average. SMA helps to identify existing price trend. If the prices are trading above the 21-period and 50-period moving average, then it shows prices are currently trading in a bullish trend.

The Black colour line in the chart’s lower segment reflects the Relative Strength Index (14-Period) which indicates price momentum and signals momentum in trend. A reading of 70 or above suggests overbought status while a reading of 30 or below suggests an oversold status.

The Blue colour bars in the chart’s lower segment show the volume of the stock. The volume is the number of shares that changed hands during a given day. Stocks with high volumes are more liquid than stocks with lesser volume as liquidity in stocks helps in easier and faster execution of the order.

The Orange colour lines are the trend lines drawn by connecting two or more price points and used for trend identification purposes. The trend line also acts as a line of support and resistance.

Technical Indicators Defined: -

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.

Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.

Stop-loss: It is a level to protect against further losses in case of unfavorable movement in the stock prices.

The reference date for all price data, currency, technical indicators, support, and resistance levels is April 24, 2024. The reference data in this report has been partly sourced from REFINITIV.

Abbreviations

CMP: Current Market Price

SMA: Simple Moving Average

GBP: British pound sterling

GBX: British pence sterling

RSI: Relative Strength Index

USD: United States dollar

Note: Trading decisions require a thorough analysis by individuals. Technical reports in general chart out metrics that may be assessed by individuals before any stock evaluation. The above are illustrative analytical factors used for evaluating stocks; other parameters can be looked at along with additional risks per se. Past performance is neither an indicator nor a guarantee of future performance.